Articolul precedent |
Articolul urmator |
405 8 |
Ultima descărcare din IBN: 2023-06-03 17:42 |
SM ISO690:2012 FEGHIU, Veronica, ROBU, Maria, TOMACINSCHII, Victor, BURUIANA, Sanda, POPESCU, Maria, DUDNIC, Cristina. Rezultatele tratamentului limfoamelor Non-Hodgkin agresive cu afectarea primară a ganglionilor limfatici abdominali. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 217. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 217-217 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Non-Hodgkin's lymphomas (NHL) are malignant tumors of lymphatic tissue. One of the primary involvements of NHL is abdominal lymph nodes. Their frequency constitutes 7.6 8.2%. Objective of the study. To evaluate aggressive NHL with primary abdominal lymph nodes involvement treatment results. Material and Methods. Treatment outcomes were studied in 37 patients with aggressive NHL with primary abdominal lymph nodes involvement, aged between 25 and 73 years. Polychemotherapy (PChT) cycles were used for treatment: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) - in 24 patients and rituximab + CHOP (R-CHOP) - in 13 patients. Results. Complete remissions were obtained in 48.7% of cases. Complete remissions rate (CRR) was higher (69.2%) when PChT R-CHOP was administered, comparing to patients in whom PChT CHOP (37.5%) was used. Progression-free survival (PFS) over 5 years was higher in patients who recieved PChT R-CHOP (74.2%). PFS in the same terms in cases when PChT CHOP was given was equal to 59.0%. Conclusion. Adding anti-CD20 monoclonal antibodies (rituximab) to the standard PChT CHOP regimen contributed significantly to the increase of CRR and PFS. |
||||||
Cuvinte-cheie Non-Hodgkin lymphoma, treatment, limfoame non-Hodgkin, Tratament |
||||||
|
DataCite XML Export
<?xml version='1.0' encoding='utf-8'?> <resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'> <creators> <creator> <creatorName>Feghiu, V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Robu, M.V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Tomacinschii, V.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Buruiana, S.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Popescu, M.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> <creator> <creatorName>Dudnic, C.</creatorName> <affiliation>Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“, Moldova, Republica</affiliation> </creator> </creators> <titles> <title xml:lang='ro,en'>Rezultatele tratamentului limfoamelor Non-Hodgkin agresive cu afectarea primară a ganglionilor limfatici abdominali</title> </titles> <publisher>Instrumentul Bibliometric National</publisher> <publicationYear>2020</publicationYear> <relatedIdentifier relatedIdentifierType='ISBN' relationType='IsPartOf'></relatedIdentifier> <subjects> <subject>Non-Hodgkin lymphoma</subject> <subject>treatment</subject> <subject>limfoame non-Hodgkin</subject> <subject>Tratament</subject> </subjects> <dates> <date dateType='Issued'>2020</date> </dates> <resourceType resourceTypeGeneral='Text'>Conference Paper</resourceType> <descriptions> <description xml:lang='en' descriptionType='Abstract'><p>Background. Non-Hodgkin's lymphomas (NHL) are malignant tumors of lymphatic tissue. One of the primary involvements of NHL is abdominal lymph nodes. Their frequency constitutes 7.6 8.2%. Objective of the study. To evaluate aggressive NHL with primary abdominal lymph nodes involvement treatment results. Material and Methods. Treatment outcomes were studied in 37 patients with aggressive NHL with primary abdominal lymph nodes involvement, aged between 25 and 73 years. Polychemotherapy (PChT) cycles were used for treatment: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) - in 24 patients and rituximab + CHOP (R-CHOP) - in 13 patients. Results. Complete remissions were obtained in 48.7% of cases. Complete remissions rate (CRR) was higher (69.2%) when PChT R-CHOP was administered, comparing to patients in whom PChT CHOP (37.5%) was used. Progression-free survival (PFS) over 5 years was higher in patients who recieved PChT R-CHOP (74.2%). PFS in the same terms in cases when PChT CHOP was given was equal to 59.0%. Conclusion. Adding anti-CD20 monoclonal antibodies (rituximab) to the standard PChT CHOP regimen contributed significantly to the increase of CRR and PFS.</p></description> <description xml:lang='ro' descriptionType='Abstract'><p>Introducere. Limfoamele non-Hodgkin (LNH) sunt tumori maligne ale țesutul limfatic. Una din localizările primare ale LNH sunt ganglionii limfatici abdominali. Frecvența lor constituie 7,6 – 8,2 %. Scopul lucrării. Studierea rezultatelor tratamentului LNH agresive cu afectarea primară a ganglionilor limfatici abdominali. Material și Metode. Au fost studiate rezultatele tratamentului la 37 de pacienți cu LNH agresive cu afectarea primară a ganglionilor limfatici abdominali, cu vârsta între 25-73 ani. Pentru tratament au fost utilizate cicluri de polichimioterapie (PChT): CHOP (ciclofosfamidă, doxorubicină, vincristină, prednisolon) -la 24 de pacienți și rituximab + CHOP (R-CHOP) -la 13 bolnavi. Rezultate. Remisiuni complete au fost obținute în 48,7 % cazuri. Rata remisiunilor complete (RRC) a fost mai înaltă (69,2%) în cazurile când s-a administrat PChT R-CHOP comparativ cu pacienții la care s-a efectuat PChT CHOP (37,5%). Supraviețuirea fără progresie (SFP) peste 5 ani a fost mai înaltă la bolnavii la care s-a aplicat PChT R-CHOP (74,2%). SFP în aceiași termeni după administrarea PChT CHOP a constituit 59,0%. Concluzii. Asocierea anticorpilor monoclonali anti-CD20 (rituximab) la schema standard de PChT CHOP, a contribuit esențial la majorarea RRC și a SFP.</p></description> </descriptions> <formats> <format>application/pdf</format> </formats> </resource>